A ngiotensinogen (AGT) is a 485 amino acid (including a 33 amino acid signal peptide) protein in humans. The commonly ascribed function of AGT is to be cleaved by renin to provide angiotensin I (Ang I), the 10 N-terminal amino acids, from which Ang II and other downstream bioactive angiotensin peptides are produced. 1 Although the predominant function of AGT is to provide the 10 N-terminal amino acids for releasing Ang I, there is an evidence that the remaining 442 amino acids (98% of AGT, termed des(Ang I)AGT) have biological functions. These include the ability of intact AGT or des(Ang I)AGT to inhibit angiogenesis in an Ang II-independent manner. [2] [3] [4] [5] [6] [7] Although AGT has some sequence identity to serpins, this does not account for its antiangiogenic effects because AGT lacks the ability to inhibit serine proteases. 3 The renin angiotensin system plays critical roles in a wide range of physiological and pathophysiological functions. It is well known that Ang II regulates blood pressure and sodium/ water homeostasis. Ang II also promotes atherosclerotic development independent of its effects on blood pressure. [8] [9] [10] Conversely, inhibition of Ang II production or its interaction with Ang II type 1 (AT1) receptors attenuates the development of atherosclerosis. 8, 11, 12 As demonstrated in previous studies, 8, [11] [12] [13] elevated blood pressure and development of atherosclerosis are Ang II-dependent responses in low density lipoprotein (LDL) receptor −/− mice fed a saturated fatenriched diet (termed Western diet in this article).
AGT-deficient mice were developed in the 1990s.
this mouse model. To provide insights into the biology of AGT, we developed floxed mice to enable cell-specific and temporal deletion of AGT. 16, 17 In the initially developed floxed mice, we retained the neomycin cassette in the construct, which resulted in development of a hypomorphic mouse expressing a small percent of AGT mRNA and protein, compared with their wildtype littermates. Removal of the neomycin cassette restored plasma AGT concentrations to normal and enabled development of mice with hepatocyte-or adipocyte-specific deletion of AGT. [16] [17] [18] In addition to genetic engineering of the mouse AGT, second-generation antisense oligonucleotides (ASOs) were developed to inhibit AGT mRNA in adult mice. We also compared AGT inhibition with a human renin inhibitor, aliskiren, which effectively prevents generation of Ang I and its downstream angiotensin peptides. 8 Therefore, roles of AGT independent of its downstream angiotensin products were determined by comparisons between reduction of AGT protein abundance and inhibition of renin cleavage. These multiple approaches have provided evidence that AGT has Ang II-independent effects. To determine a potential basis for the Ang II-independent effects, we analyzed the structural features of AGT and demonstrated that the core serpin domain, des(Ang I)AGT, of AGT was attributed to Ang II-independent effects of AGT.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Global Reductions of AGT Reduced Systolic Blood Pressure, Atherosclerosis, Body Weight Gain, and Liver Steatosis in Hypercholesterolemic Mice
To study AGT function, we generated AGT-floxed mice [16] [17] [18] by placing 3 LoxP sites encompassing exon 2 of the mouse AGT gene and a neo cassette in intron 2 ( Figure IA in the onlineonly Data Supplement). These AGT-floxed mice were then cross-bred with LDL receptor −/− mice. Unexpectedly, the resulting mice had greatly reduced AGT mRNA abundance in all tissues, including liver, kidney, and epididymal adipose tissue ( Figure IB in the online-only Data Supplement). Also, these mice had <10% of plasma AGT concentrations compared with their wild-type littermates ( Figure 1A) , and >10-fold increases in plasma renin concentrations ( Figure 1B) . Therefore, these mice were deemed to be hypomorphic for AGT (hypoAGT). Unlike global AGT-deficient mice, 15, 19 hypoAGT mice had normal neonatal survival rate, normal growth rates, and no overt renal morphological defects.
To assess the effects of global AGT reductions on atherosclerosis, male hypoAGT mice and their wild-type littermates in an LDL receptor −/− background were fed a Western diet for 12 weeks. All mice fed Western diet were grossly hypercholesterolemic, as demonstrated by their plasma total cholesterol concentrations. Plasma cholesterol concentrations were modestly lower in hypoAGT mice, attributed to decreased non-high density lipoprotein cholesterol ( Figure IIA and IIB in the online-only Data Supplement). hypoAGT mice had low systolic blood pressure ( Figure 1C ) and developed minimal atherosclerotic lesions, compared with their wild-type littermates ( Figure 1D ; Figure IIC and IID in the online-only Data Supplement).
For all study mice, body weights were measured weekly to monitor their general health. Although body weights at baseline when fed a normal laboratory diet were not significantly different between the 2 genotypes, hypoAGT mice gained much less body weight, compared with their wild-type littermates during Western diet feeding ( Figure 1E ). On the basis of body composition analysis using EchoMRI, body weight difference was attributed to diminished fat mass gain ( Figure 1F ), which was confirmed by direct measurement of adipose tissue weights of epididymal, retroperitoneal, and inguinal regions at termination ( Figure III in the online-only Data Supplement).
We also observed significantly lower liver weights in hypoAGT mice at termination ( Figure 1G ), consistent with lack of liver steatosis in hypoAGT mice, as manifested by lower liver triglyceride content measured by mass spectrometry ( Figure 1H ) and direct visualization by hematoxylin and eosin staining ( Figure 1I ).
AGT Deficiency in Bone Marrow-Derived Leukocytes Had No Effects on Systolic Blood Pressure, Atherosclerosis, and Body Weight Gain in Hypercholesterolemic Mice
AGT is synthesized by many cell types, 20 including macrophages, 21 an inflammatory cell type influencing the development of atherosclerosis and obesity. 22, 23 Our previous studies have demonstrated that renin 8 and angiotensin-converting enzyme (ACE) 24 in bone marrow-derived cells contribute to atherosclerosis. To determine whether AGT in macrophages contributes to the phenotypes observed in hypoAGT mice, we performed bone marrow transplantation, in which LDL receptor −/− mice were replenished with bone marrow-derived cells from either wild-type or AGT whole body-deficient mice. Genotypes of AGT in bone marrow-derived cells of recipient LDL receptor −/− mice were confirmed by polymerase chain reaction ( Figure IVA Because hepatocytes are assumed to be the major source for plasma AGT, we examined whether hepatocyte-specific deletion of AGT would recapitulate phenotypes of hypoAGT mice. After removal of the neomycin cassette, AGT-floxed mice in an LDL receptor −/− background were bred to transgenic mice expressing Cre under the control of an albumin promoter to generate hepatocyte-specific AGT-deficient (hepAGT−/−) mice ( Figure VA in the online-only Data Supplement). 16 We confirmed that AGT deficiency was specific to hepatocytes in hepAGT−/− mice by examining mRNA abundance of AGT in major AGT-expressing tissues, including liver, kidney, and epididymal adipose tissue (Figure VB in the online-only Data Supplement). Hepatocyte-specific AGT deficiency led to a profound reduction in plasma AGT concentrations ( Figure 2A) and elevated plasma renin concentrations ( Figure 2B ) in a similar manner as in hypoAGT mice.
After the same experimental procedures for hypoAGT mice, we evaluated the phenotypes observed in hepAGT−/− mice and their wild-type littermates. Although hepatocytespecific deficiency of AGT had no effects on plasma total cholesterol concentrations and lipoprotein distribution ( Figure  VIA and VIB in the online-only Data Supplement), it led to lower systolic blood pressure and attenuation of atherosclerosis to comparable magnitudes as observed in hypoAGT mice (Figure 2C and 2D ; Figure VIC and VID in the onlineonly Data Supplement). Hepatocyte-specific deficiency of AGT led to less body weight gain during fed Western diet. Attenuation of body weight gain was because of reductions in fat mass gain, as demonstrated by both EchoMRI ( Figure 2E and 2F) and direct measurements of major white adipose tissue weights at termination. Liver weights and triglyceride contents were reduced profoundly in hepAGT−/− mice, compared with their wild-type littermates ( Figure 2G Supplement). Together, our findings demonstrate that hepatocyte-derived AGT is responsible for reductions in atherosclerosis, blood pressure, body weight gain, and liver steatosis phenotypes that were observed in hypoAGT mice.
To determine whether replenishment of AGT in hep-AGT−/− adult mice would restore phenotypes as observed in Western diet-fed hepAGT+/+ mice, we injected adenoassociated virus (AAV) containing either a null insert or a mouse wild-type AGT into hepAGT−/− mice, as described previously. 16 Plasma AGT concentrations in hepAGT−/− mice receiving AAV vector expressing wild-type AGT were comparable with hepAGT+/+ littermates ( Figure 
Metabolic and Genetic Parameters Associated With Phenotypes in Mice With Whole Body or Hepatocyte-Specific Reductions in AGT
Neither global reductions of AGT nor hepatocyte-specific deficiency of AGT affected intestinal fat absorption and food intake ( Figure IXA , IXB, IXD, and IXE in the online-only Data Supplement). Therefore, reductions in body weight gain during fed Western diet were not because of reductions in energy intake. Physical activity was increased in hypoAGT mice, but not in hepAGT−/− mice ( Figure IXC and IXF in the online-only Data Supplement). Consistent with less body weight gain, hepAGT−/− mice had increased oxygen consumption and carbon dioxide production normalized to whole body weight (Figure X in the online-only Data Supplement) or lean body weight (data not shown).
To determine potential genes that may be associated with reduced body weight gain and prevention of liver steatosis in hepAGT−/− mice, we performed global gene profiling using whole mouse genome gene chips on liver, epididymal adipose tissue, and interscapular brown adipose tissue collected from hepAGT+/+ or −/− mice fed Western diet for 12 weeks. A total of 35 000 RefSeq transcripts were screened. A clustered heat map was generated with a criterion of ≥1. XII and Table  II in the online-only Data Supplement). mRNA abundance of angiopoietin 1 and PGC1a (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) were increased in epididymal adipose tissues of hepAGT−/− mice ( Figure XII and Table  III in the online-only Data Supplement). mRNA abundance of leptin, but not adiponectin, was reduced in brown adipose tissue of hepAGT−/− mice, whereas abundance of neither adiponectin nor leptin was changed in epididymal adipose tissue ( Figure  XIIIA and XIIIB in the online-only Data Supplement). Plasma concentrations of adiponectin were increased, and plasma leptin concentrations were decreased in hepAGT−/− mice ( Figure  XIIIC in the online-only Data Supplement). Despite a profound difference of liver triglyceride content, most genes determined in liver had no difference in mRNA abundance, except that peroxisome proliferator-activated receptorγ was lower in liver of hepAGT−/− mice, compared with hep-AGT+/+ mice (Table IV in 
Inhibition of AGT Synthesis by SecondGeneration ASOs Compared With Inhibition of Renin Cleavage of AGT
We developed 2 second-generation ASOs targeting different sites (named AGT-1 and AGT-2, respectively) on the mRNA of AGT in adult mice. To evaluate effects of AGT ASOs on blood pressure, atherosclerosis, and body weight gain, LDL receptor −/− mice were administered a control ASO or either AGT ASO (50 mg/kg per week intraperitoneal injections), starting 1 week before Western diet feeding. Intraperitoneal injection of either AGT ASO profoundly reduced mRNA abundance of AGT in liver, as well as in kidney and epididymal adipose tissue ( Figure  XVA in the online-only Data Supplement). Plasma AGT concentrations were reduced by >90% in mice injected with either AGT ASO, compared with mice injected with control ASO. This reduction was apparent after 3 weeks of injections ( Figure 3A ; Figure XVB in the online-only Data Supplement). Conversely, plasma renin concentrations were profoundly increased to similar levels as observed in hypoAGT and hepAGT−/− mice ( Figure 3B ). All study mice were hypercholesterolemic, and mice administered AGT-2, but not AGT-1, had lower plasma cholesterol concentrations that were attributed to reduced non-high density lipoprotein cholesterol ( Figure XVIA and XVIB in the online-only Data Supplement). Consistent with blood pressure lowering and antiatherogenic effects of inhibiting renin, ACE, or AT1 receptors, 12 AGT ASO administration lowered systolic blood pressure and profoundly reduced atherosclerotic lesions, compared with mice injected with control ASO (Figure 3C and 3D; Figure XVIC -XVIE in the online-only Data Supplement).
In agreement with our genetic mouse models, adult (8-10 weeks old) LDL receptor −/− mice fed Western diet that were injected with either AGT ASO had diminished body weight gain, compared with mice injected with control ASO (Figure 3E and 3G) . Although lean mass was not different between mice injected with control ASO and AGT ASOs, fat mass gain was diminished in mice injected with either AGT ASO ( Figure 3F ), which was confirmed by directly measuring tissue weights of epididymal, retroperitoneal, and inguinal fat at termination (Figure XVII in the online-only Data Supplement). Morphometric analysis of epididymal fat showed that mice injected with AGT ASO-1 had smaller adipocytes ( Figure 3H) .
Reduction of AGT protein decreases the synthesis of all downstream angiotensin peptides, which is comparable with effects of aliskiren, a renin inhibitor to prevent renin cleavage of AGT. Therefore, we compared effects of renin inhibition (aliskiren) with reduction of AGT protein (AGT ASO data presented in Figure 3 ). Constant renin inhibition was achieved by infusion of aliskiren via mini osmotic pumps throughout the experimental period. Aliskiren infusion, at a rate that profoundly increased plasma renin concentrations and decreased blood pressure and atherosclerosis as reported previously, 12 did not significantly change plasma total AGT concentrations ( Figure 4A ). Aliskiren infusion also had no significant effects on body weight gain and liver triglyceride concentrations ( Figure 4B and 4C) in male LDL receptor −/− mice fed Western diet for 12 weeks.
Comparison of AGT Reduction and Renin Inhibition in Mice With Pre-Existing Adiposity
To determine whether inhibition of AGT regulates pre-existing atherosclerosis and obesity, LDL receptor −/− mice were fed Western diet for 12 weeks to induce atherosclerosis and body weight gain. Mice were then randomized into 2 groups receiving weekly injection of either control ASO or AGT ASO (AGT-1) while being maintained on Western diet for another 12 weeks. Another group of LDL receptor −/− mice were also fed Western diet before being subcutaneously infused with either PBS (vehicle) or the renin inhibitor (aliskiren). Inhibition of renin enzymatic activity by aliskiren was confirmed by measuring plasma renin concentrations (vehicle versus aliskiren: 6.2±1.9 versus 25.8±4.6 ng/mL; P=0.002 by Mann-Whitney Rank Sum Test). These 2 modes of pharmacological inhibition had comparable effects on reducing blood pressure ( Figure 5A and 5C) and established atherosclerotic lesions ( Figure XVIII in the online-only Data Supplement). In contrast to continuous body weight gain in mice receiving control ASO, AGT inhibition ceased body weight gain 2 weeks after initiating AGT ASO injection, and further led to weight loss at a constant rate for 6 weeks, and maintained body weight afterwards ( Figure 5B ). In contrast, renin inhibition had no significant effect on body weight gain ( Figure 5D ).
The Core Serpin Domain of AGT Contained Highly Conserved Sequences Beyond the ReninBinding Regions and Had Biological Function
We have identified profound Ang II-independent effects of AGT. Because AGT has a large conserved serpin domain (the des[Ang I]AGT part of AGT), 25 we hypothesized that this region governs the Ang II-independent function. To identify regions of the serpin domain that may be critical for its function, we performed a bioinformatic analysis, identifying surface residues conserved across protein orthologs. We aligned the sequences of AGT from human, rat, mouse, and zebrafish, which diverge significantly with 22% residue identity, and mapped onto the structure of AGT. 26 As expected, the N-terminal Ang I encoding region ( Figure 6 , green color) and core hydrophobic residues ( Figure 6 , purple color) necessary for stabilizing the protein fold are conserved. In addition, 3 highly conserved surface regions were found in the serpin domain. One conserved region was observed to be in the region that directly contacts renin ( Figure 6 , blue color) and, therefore, may contribute to the Ang I-dependent function of AGT. It is unclear whether the interaction of AGT and renin solely influences the release of Ang I or whether there are other effects of this interaction. Intriguingly, the face distal to the renin-binding surface also shows high conservation. Three strictly conserved residues on the central β-sheet face, K253, H274, and E422, are remote in sequence but close in space ( Figure 6, red color) . Furthermore, the loop formed by residues 291-301 is highly conserved (Figure 6 , gold color) and contains strictly conserved solvent accessible hydrophobic residues W292 and V299 along with strictly conserved S298. These regions, with differentially, highly conserved surface patches, bear the hallmarks of important protein interaction regions.
To directly determine effects of the core serpin domain on Ang II-independent effects of AGT, we infected hepAGT−/− mice with an AAV-expressing mouse des(Ang I)AGT. These mice were fed Western diet for 12 weeks, starting 2 weeks after AAV injections. des(Ang I)AGT expression had no effect on plasma renin concentrations ( Figure 6B In contrast, body weight gain ( Figure 6D ), liver weight ( Figure 6E ), and liver triglyceride content ( Figure 6F ) in hep-AGT−/− mice repopulated with des(Ang I)AGT were comparable with hepAGT+/+ mice, whereas hepAGT−/− mice infected with a null insert had significantly less body weight gain and liver steatosis ( Figure 6D-6F ). These data demonstrate that the core serpin domain, des(Ang I)AGT, mediates the observed Ang II-independent function of AGT.
Discussion
In this study, we have demonstrated that inhibition of AGT decreases blood pressure and atherosclerosis, as expected in conditions with diminished availability of Ang II in mice with an LDL receptor −/− background fed a Western diet. Lowering AGT synthesis also profoundly reduces body weight gain and liver steatosis. These effects are consistently observed across a platform of genetically engineering and pharmacological interventions to inhibit AGT. The features of diminished body weight gain and liver steatosis, in mice with reduced plasma AGT concentrations, are Ang II-independent because renin inhibition has no discernible effects on body weight gain and liver steatosis in same strain of mice fed same Western diet, but has comparable effects on the Ang II-dependent effects of blood pressure and atherosclerosis. We also provide direct demonstration that des(Ang I)AGT, the core serpin domain of AGT, contributes to body weight gain and liver steatosis, but not Ang II-dependent effects. Collectively, these multiple approaches are consistent with AGT having both Ang II-dependent and Ang II-independent biological functions. AGT is expressed in many cell types, tissues, and organs. Macrophage-mediated inflammation is one mechanism for both atherosclerosis and obesity. 22, 27 Although AGT mRNA and protein are present in macrophages, 8 deficiency of AGT in bone marrow-derived cells does not influence atherosclerosis and body weight gain in LDL receptor −/− mice. Adipocytes are an abundant source for AGT. 17, 18, 28 However, overexpression or deficiency of AGT in an adipocyte-specific manner has minimal effects on body weight gain during saturated fatenriched diet feeding. 17, 18, 29 AGT is also produced in kidneys. A recent study has reported that AGT in hepatocytes, rather than AGT produced in kidneys, is responsible for renal Ang II release and normal renal function. Our studies, using conditional gene depletion through Cre driven by an albumin promoter, provide direct evidence that hepatocytes are the major source for AGT contributing to high blood pressure, atherosclerosis, body weight gain, and liver steatosis.
Whole body genetic deficiency of the major renin angiotensin components (AGT, renin, ACE, or combined AT1a and AT1b receptors) leads to diminished body weight gain. 19, [30] [31] [32] Unlike this study, these reductions in body weight occur when fed either normal or fat-enriched diets. 19, [30] [31] [32] Also, all these genetic-deficient mouse models have low neonatal survival rate with severe developmental problems because Ang II plays a critical role in embryonic development. 15, [32] [33] [34] [35] [36] [37] Therefore, complete deficiency of these major renin angiotensin system proteins leads to abnormalities that confound interpretation of reduced body weight gain. The consistency of body weight reductions in mice with genetic deficiencies of major renin angiotensin components contrasts with the phenotypes of pharmacological inhibition of these same proteins. A small number of studies using renin, ACE, or AT1 receptor inhibition have reported modest reductions in saturated fat diet-induced body weight gain in mice, [38] [39] [40] [41] [42] [43] [44] whereas the vast majority of studies using pharmacological inhibition of renin, ACE, or AT1 receptors in mice fed a saturated fat diet have failed to observe any effect on body weight (>60 papers including 8, 12, 40, [45] [46] [47] ). These data from mice are consistent with no data implicating body weight changes in humans treated with renin angiotensin system pharmacological inhibitors.
In contrast to low neonatal survival rate and severe developmental issues in mice with global genetic deficiency of AGT, hypomorphic and hepatocyte-specific deficient AGT mice used in this study have normal neonatal survival rate, grossly normal kidney structure, and comparable growth to wild-type mice when fed a normal laboratory diet. Because the albumin Cre transgene is fully activated 6 weeks after birth, 48 depletion of the AGT gene in hepatocytes of hepAGT−/− mice occurs in adult mice, thus reducing the potential for developmental defects that are seen in mice with whole body deficiency of AGT. Furthermore, repopulation of AGT in hepAGT−/− mice using an AAV induced expression led to complete restoration of all phenotypes seen in AGT wild-type mice. In addition to genetic mouse models, consistent effects of a pharmacological approach using ASOs to degrade AGT mRNA, thereby reducing protein synthesis in adult mice, provide compelling evidence that decreased body weight gain observed in mice with AGT genetic deficiency is not attributed to impairment of normal growth and development. Our studies have also demonstrated that AGT protein not only prevents adipose expansion in mice fed a diet enriched in saturated fat but also regresses pre-existing adiposity.
Mechanisms by which AGT contributes to body weight gain and liver steatosis are unclear. In contrast to findings in whole body renin-deficient mice, 30 we were unable to demonstrate any change in food consumption or fat absorption in both hypoAGT mice and hepAGT−/− mice. Therefore, body weight phenotype of these 2 AGT genetic mice is not because of energy intake. A previous study detected increased physical activity in whole body AGT-deficient mice that could account for increased energy expenditure. 19 Both hypoAGT and hep-AGT−/− mice have enhanced energy expenditure, compared with their wild-type littermates. Although hypoAGT mice also have increased physical activity, this is not observed in hepAGT−/− mice. Gene profiling analysis exhibits that most striking differences are in brown adipose tissue, including enhanced expression of UCP-1 and VEGF-A in hepAGT−/− mice. In agreement with mRNA abundance of VEGF-A in brown adipose tissue, plasma VEGF-A concentrations are increased in hepAGT−/− mice fed Western diet. These findings infer that diminished body weight gain in hepAGT−/− mice is associated with enhanced thermogenesis and angiogenesis. One of our future goals is to explore specific mechanisms by which AGT contributes to obesity through these 2 processes.
To approach the basis for Ang II-independent effects, we performed an analysis of conserved sequences of AGT, which discovered highly conserved regions outside the domains of AGT-renin interaction, namely, the serpin domain of AGT (or des[Ang I]AGT). In mice lacking circulating AGT, repopulation of des(Ang I)AGT does not affect atherosclerosis, an Ang II-dependent effect of AGT, but results in increases of body weight gain and liver steatosis that are comparable with the phenotypes in their wild-type littermates. These findings provide direct evidence that des(Ang I)AGT has biological functions. The functionality of conserved sequences of this serpin domain will be explored in future studies including that we will repopulate hepAGT−/− mice with AGT mutants of identified conserved sequences, as we have described in a recent study to determine effects of a conserved disulfide bond C18-C138. 16 In summary, highly consistent phenotypes are confirmed using different modes of decreasing AGT protein abundance either during development or in adult mice. By comparison with renin inhibition, in which plasma AGT protein concentrations are conserved but unable to provide Ang I, we have demonstrated effects of AGT reductions beyond its most commonly ascribed function of providing bioactive angiotensin peptides. These Ang II-independent effects of AGT may provide enhanced benefit in patients with hypertensive obesity or metabolic syndrome, compared with renin and other renin angiotensin inhibitors. Identification of conserved domains unrelated to AGT-renin interaction will provide structural evidence on Ang II-independent biological effects of AGT.
